Mizuho Securities Sticks to Their Buy Rating for Atara Biotherapeutics (ATRA)

Mizuho Securities reiterated a Buy rating for Atara Biotherapeutics (ATRA) on June 18, maintaining a $18.00 price target. The stock closed the prior Thursday at $10.07, according to the report. The article cites TipRanks data indicating analyst Salim Syed has an average return of -1.0% with a 42.91% success rate, covering the Healthcare sector and names including Century Therapeutics and Assembly Biosciences. For Atara, the consensus shown by TipRanks is Moderate Buy, with an overall price-target consensus of $13.67. Financially, Atara reported quarterly revenue of $516 thousand for the quarter ended March 31, alongside a GAAP net loss of $4.15 million. In the prior year period, it recorded revenue of $98.15 million and a GAAP net profit of $38.01 million. The piece also notes negative insider sentiment, including a CAO sale of 2,414 shares for $22,015.68 in the prior month.